Retina Research Institute

At New England Retina Consultants, we are committed to providing the highest quality retina care to our patients. To accommodate a growing and important aspect of exceptional retinal care, we have opened a new facility, completely dedicated to retinal investigations.

The Retina Research Institute at New England Retina Consultants has a strong commitment to the advancement of treatments for retinal conditions. If you or someone you know is interested in more information about our clinical trial program, please contact our research coordinator, Rachel O’brien, 413-788-6044 or

Enrolling Trials
DAZZLE (Kodiak Sciences, Inc) – A Phase 2, Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center Study to Investigate the Efficacy and Safety of Repeated Intravitreal Administration of KSI-301 in Subjects with Neovascular (Wet) Age-related Macular Degeneration

ADX-2191-PVR (Aldeyra Therapeutics, Inc) – A Multicenter, Randomized, Controlled, Prospective, Adaptive Phase 3 Clinical Trial of Repeated Intravitreal Injections of ADX-2191 Versus Standard of Care For The Prevention of Proliferative Vitreoretinopathy

MERLIN (Novartis) – A multi-center, double masked phase 3a study to assess safety and efficacy of brolucizumab 6mg q4 weeks compared to aflibercept 2mg q4 weeks in patients with neovascular age-related macular degeneration with persistent retinal fluid

KESTREL (Novartis) – A Two-Year, Three-Arm, Randomized, Double-Masked,
Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema

OAKS-APL2-304 (Apellis) – A phase III, multi-center, randomized, double-masked, sham-controlled study to compare the efficacy and safety of intravitreal APL-2 therapy with sham injections in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

DERBY-APL2-303 (Apellis) -A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)”

PANDA2 (Chengdu Kanghong Biotechnology) – A multi-center, double-masked, randomized, dose-ranging trial to evaluate the efficacy and safety of Conbercept intravitreal injection in subjects with neovascular age-related macular degeneration

OPH2003 (Ophthotech)- A phase 2/3 randomized, double-masked, controlled trial to assess the safety and efficacy of intravitreous administration of Zimura (Anti-C5 apatmer) in subjects with geographic atrophy secondary to dry age-related macular degeneration

Renexus (Neurotech): A phase III multicenter randomized, sham controlled study to determine the safety and efficacy of Renexus in macular telangiectasia type 2

MACTEL: A natural history observation and registry study of macular telangiectasia type 2; the mactel study

Upcoming Trials

Astellas – ASP7317 – A Staged Study Incorporating a Phase 1b, Multicenter, Unmasked, Dose Escalation Evaluation of Safety and Tolerability
and a Phase 2, Multicenter, Unmasked, Randomized, Parallel-Group, Controlled, Proof of Concept Investigation of Efficacy and Safety of ASP7317 for Atrophy Secondary to Age-related Macular Degeneration-Protocol 7317-CL-0003

Allergan – BrIMonidine DDS Assessment: GeographIc Atrophy SecoNdary to Age-related Macular DEgeneration (IMAGINE Study)

Novartis CRTH258D2301 – A 96-week, two-arm, randomized, single-masked, multi-center, phase III study assessing the efficacy and safety of brolucizumab 6 mg compared to panretinal photocoagulation laser in patients with proliferative diabetic retinopathy

Completed Trials

Comparison between retinal images captured by NOTAL-OCT V2.5 and Zeiss
Cirrus/Heidelberg Spectralis SDOCT

TOPAZ (Clearside Biomedical)- A randomized, masked, controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in combination with an intravitreal anti-VEGF agent in subjects with retinal vein occlusion

Comparative Study of Canon OCT-HS100 with OCT Angiography and the RTVue XR OCT with Avanti with AngioVue Software/ORA Study

Apex Study (Tyrogenex) – A randomized, double-masked, placebo-controlled, dose-finding, non-inferiority study of X-82 plus prn ivt anti-VEGF compared to prn ivt anti-VEGF monotherapy in neovascular AMD

Eyetech EOP1004 (Macugen)
Genentech MARINA (Lucentis)
Genentech ANCHOR (Lucentis)
Genentech PIER (Lucentis)
Genentech HORIZON (Lucentis)
Genentech SAILOR (Lucentis)
Allergan Posurdex 206207-001 (Ozurdex)
Allergan Posurdex 206207-009 (Ozurdex)
Regeneron READ 2 (Eylea)
Genentech SEVEN-UP (Lucentis)